• Arcus Biosciences CFO Robert C. Goeltz II sold 7,763 common shares on May 11, 2026 at USD 25.63.
• Holdings stood at 84,161 shares following transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001653881-26-000005), on May 12, 2026, and is solely responsible for the information contained therein.